Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer

Crizotinib, the first clinically designed and synthesized as a tyrosine kinase inhibitor targeting mesenchymal–epithelial transition factor, indicating marked anticancer activity in patients with advanced, anaplastic lymphoma kinase-positive non-small-cell lung cancer, was approved by the US Food an...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Liting, Zhang, Haijun, Shao, Weiwei, Chen, Baoan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599072/
https://www.ncbi.nlm.nih.gov/pubmed/26491259
http://dx.doi.org/10.2147/DDDT.S91988

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599072/
https://www.ncbi.nlm.nih.gov/pubmed/26491259
http://dx.doi.org/10.2147/DDDT.S91988

Ejemplares similares